Cite
HARVARD Citation
Knight, E. et al. (2022). Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet neurology. 21 (5), pp. 417-427. [Online].